August 21-22, 2019
Boston, MA

Workshop A
August 21 2018

09.00 - 12.00
Organs-on-Chips: A Developer’s Masterclass
Workshop Leader: John Wikswo, Gordon A. Cain University Professor & Director, VIIBRE

Following the success of the session in the past two event iterations, John will be back once more to give an in depth analysis of how best to approach and develop microfluidic devices with a focus on interconnected systems and their use within industry. This workshop will help you realize the unlimited potential of engineered tissue models for replicating organ system signaling and dynamics.

Leave this workshop with:

  • A greater understanding of the key challenges facing the development of microfluidic systems and how to overcome them
  • An in depth insight into how to model, interconnect, test, and control these biological systems consistent with allometric, biochemical and/or functional scaling
  • Knowledge of how best to achieve noninvasive readouts with the latest advances in imaging, sensor, and multi-omic technologies

John Wikswo, Gordon A. Cain University Professor & Director, VIIBRE

John Wikswo is a university professor at Vanderbilt University and the founding director of the Vanderbilt Institute for Integrative Biosystems Research and Education. His work on organs-on-chips focuses on the neurovascular unit, cardiac tissue, and automated devices for perfusion, control, interrogation, and interconnection of organ chips.

Workshop B
August 21 2018

09.00 - 12.00
3D Printing & Bioprinting for Complex Tissue Engineering
Workshop Leader: Bhushan Mahadik, Assistant Director NIH/NIBIB Center for Engineering Complex Tissues (CECT) , University of Maryland

Bioprinted tissue constructs have great potential as platforms to improve our understanding of cell and tissue-level biology for various applications. However, numerous challenges exist in adopting and utilizing the variety of technologies and approaches within development workflows. The objective of this workshop is to introduce tools and techniques related to 3D Printing and Bioprinting in order to fabricate complex tissue architecture that can serve as in vitro models capable of recapitulating native biology.

Leave this workshop with:

  • An in-depth insight into a variety of tools and techniques in additive manufacturing for generating tissue models
  • Exploration into issues and strategies to mitigate material selection and printability
  • A greater understanding of 3D printing and Bioprinting principles for getting started with complex in vitro models developed

Bhushan Mahadik, Assistant Director NIH/NIBIB Center for Engineering Complex Tissues (CECT) , University of Maryland

Workshop C
August 21 2018

13.00 - 16.00
Leveraging 3D In-vitro Models for ADME-Tox Studies
Workshop Leader: Edward Kelly, Associate Professor, University of Washington

Active drug metabolites and drug-drug interactions are attributed for a large percentage of drug failures. As such, representative ADME studies are essential to the drug discovery process and yet current models fall short on their pharmacokinetic profile, largely due to their over simplicity and lack of physiological relevance. Better recapitulating the physiological and metabolic properties of the in vivo environment, 3D models represent significant advantages for detection of drug induced toxicities.

This workshop will review current advances in 3D model development and use for ADME-tox with reference to
single and coupled 3D microfluidic systems.

Leave this workshop with:

  • Novel approaches utilizing chip based models for metabolite identification and enzyme mapping
  • Strategies utilizing 3d microtissues in the clearance prediction of low turnover compounds

Edward Kelly, Associate Professor, University of Washington

Workshop D
August 21 2018

13.00 - 16.00
Development of Stem Cell Organoid Models for Drug Screening Applications
Workshop Leader: Zhen Ma, Assistant Professor, Syracuse University

Human in vitro cardiac predictive of of human drug response would be a significant advancement for understanding, and developing new drugs treating cardiac diseases. Recent technical advances in human iPSC-derived 3D organoids have presented huge opportunities to bridge the in vitro and in vivo gap. Providing insights, beyond basic descriptors at the cellular level, these models are offering new insights into complex organ development and have vast applications within pharmaceutical research. With specific reference to 3D hiSPC cardiac organoids, this session will look to explore the technical advances in designing these models, applications within the basic and pharmaceutical setting as well as strategies for overcoming remaining issues to use.

Leave this workshop having:

  • Envisioned the integration of hiPSC biology, tissue engineering and gene editing technologies to develop next-gen 3D tissue models and organ-onchip systems
  • Reviewed current biofabrication technologies for creating 3D tissue models for high-throughput and high-content preclinical drug evaluation
  • Highlights on the integration of in vitro model with in silicon model for multifaceted data analysis and drug toxicity prediction.

Zhen Ma, Assistant Professor, Syracuse University